(Q34239009)

31 July 2017

title

The different reduction rate of prostate-specific antigen in dutasteride and finasteride (English)

1 reference

31 July 2017

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride (English)

1 reference

https://api.crossref.org/works/10.4111/KJU.2010.51.10.704

16 August 2024

1 reference

3

In Rae Cho

1 reference

31 July 2017

Yong Hyeuk Choi

1

1 reference

31 July 2017

Sung Yong Cho

series ordinal

2

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21031091

16 August 2024

publication date

21 October 2010

1 reference

full work available at URL

31 July 2017

https://europepmc.org/articles/pmc2963784?pdf=render

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031091

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21031091/pdf/?tool=EBI

16 August 2024

file format

Portable Document Format

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031091

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21031091/?tool=EBI

16 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031091

https://europepmc.org/articles/PMC2963784

16 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031091

https://europepmc.org/articles/PMC2963784?pdf=render

16 August 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031091

https://synapse.koreamed.org/DOIx.php?id=10.4111/kju.2010.51.10.704

16 August 2024

1 reference

https://api.crossref.org/works/10.4111/KJU.2010.51.10.704

https://synapse.koreamed.org/pdf/10.4111/kju.2010.51.10.704

16 August 2024

1 reference

https://api.crossref.org/works/10.4111/KJU.2010.51.10.704

https://icurology.org/DOIx.php?id=10.4111/kju.2010.51.10.704

16 August 2024

1 reference

https://api.crossref.org/works/10.4111/KJU.2010.51.10.704

Korean Journal of Urology

16 August 2024

published in

1 reference

31 July 2017

volume

51

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

704-708

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

31 July 2017

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Effect of dutasteride on the risk of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Changes in molecular forms of prostate-specific antigen during treatment with finasteride

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2963784

Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.

28 October 2018

1 reference

12 December 2020

Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial

1 reference

12 December 2020

Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen

1 reference

12 December 2020

Treatment of chronic prostatitis lowers serum prostate specific antigen

1 reference

12 December 2020

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride

1 reference

12 December 2020

Benign prostatic hyperplasia

1 reference

12 December 2020

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride

1 reference

12 December 2020

Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate

1 reference

12 December 2020

Identifiers

1 reference

31 July 2017

1 reference

31 July 2017

1 reference